What are the Historical Developments and Current Growth Metrics of the Nocturia Market?
The nocturia market has seen considerable growth due to a variety of factors.
• The value of the nocturia market has witnessed significant growth lately. This market will expand from $2.87 billion in 2024, growing to $3.11 billion by 2025, with a compound annual growth rate (CAGR) of 8.4%.
The expansion in the past years is primarily due to factors such as the growing cases of cardiovascular diseases, rising incidents of insomnia, an increase in the elderly population, enhanced cognizance of nocturia and associated conditions, and a rise in associated health complications.
What is the Forecasted Market Size and CAGR for the Nocturia Market?
The nocturia market is expected to maintain its strong growth trajectory in upcoming years.
• We can anticipate a robust expansion in the nocturia market in the coming years, where it's slated to reach $4.23 billion by 2029, featuring a compound annual growth rate (CAGR) of 8.0%.
The growth projection for this period is primarily tied to the escalating cases of bladder obstruction issues and urinary tract inflammation, the increasingly frequent instances of nocturia due to a range of risk factors, the role of high fluid intake patterns in exacerbating nocturia, the growing understanding of the nexus between nocturia, sleep disorders, and kidney health, and the demographic shift toward an older population. The forecast period will also spotlight notable trends such as diagnostic advancements, the emergence of new medication, a boost in research and investment earmarked for nocturia remedies, the evolution of surgical and non-surgical treatment methods, and the embrace of precision medicine.
What Key Factors and Trends Are Driving The Growth Nocturia Market?
The increasing occurrence of cardiovascular diseases is predicted to spur the expansion of the nocturia market in the future. Cardiovascular diseases (CVDs), which encompass heart disease, stroke, and hypertension, among other heart and blood vessel disorders, are prevalent due to factors like aging populations, inactive lifestyles, unhealthy eating habits, tobacco use, excessive alcohol use, obesity, hypertension, high cholesterol, diabetes, and genetic vulnerability. Nocturia is a common symptom experienced by individuals with cardiovascular diseases, thereby increasing the demand for diagnostic and treatment options. As the prevalence of cardiovascular diseases continues to grow worldwide due to aging demographics and poor lifestyle choices, there will be a heightened necessity for effective nocturia management. To illustrate, in May 2024, the Centers for Disease Control and Prevention, a government agency in the US, reported that heart disease accounted for 702,880 deaths, or 20% of all deaths in the US, in 2022. Each year, about 805,000 individuals suffer a heart attack. Of these, 605,000 are first-time instances, while 200,000 occur in those with a pre-existing history. Thus, the escalating prevalence of cardiovascular diseases is a significant driver for the growth of the nocturia market.
What Are The Market Segments In The Nocturia Market?
The nocturia market covered in this report is segmented –
1) By Drug: Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drugs
2) By Indication: Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria
3) By Causes: Urological Infection, Tumor Of The bladder, Diuretic Medications, Regular Alcohol Or coffee, Liver infection, Diabetes, Pregnancy, Other Causes
4) By End User: Hospitals, Home Care, Clinics
Subsegments:
1) By Anticholinergic Drugs: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine
2) By Desmopressin: Intranasal Desmopressin, Oral Desmopressin
3) By Antibiotics: Nitrofurantoin, Trimethoprim, Fosfomycin, Other Antibiotics
4) By Antispasmodic: Hyoscine Butylbromide, Flavoxate, Other Antispasmodics
5) By Other Drugs: Alpha-blockers, Beta-3 Agonists, Diuretics, Other Pharmacological Treatments
Pre-Book The Nocturia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Nocturia Market?
Leading organisations in the nocturia market are concentrating on creating innovative products like orally disintegrating tablets (ODTs) to boost patient comfort and adherence. ODTs are solid dosages that dissolve promptly in the mouth without the need for water, thus providing a solution for patients who struggle with swallowing. For example, Adalvo Limited, a pharmaceutical company based in Malta, introduced Desmopressin ODT in Europe in July 2024 to address conditions that result in excessive fluid loss, such as central cranial diabetes insipidus. This synthesized version of vasopressin tablet mimics the natural hormone and reduces the amount of water expelled in urine, thereby treating diabetes insipidus, excessive thirst and urination, and bedwetting. It also aids in the management of bleeding in mild to moderate hemophilia A and Von Willebrand disease through the stimulation of blood clotting factors release.
Who Are the Key Players In The Nocturia Market?
Major companies operating in the nocturia market are:
• Pfizer Inc
• Merck & Co. Inc
• AbbVie Inc
• Sanofi S.A
• GlaxoSmithKline plc
• Viatris Inc
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd
• Astellas Pharma Inc
• Eisai Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd
• Ferring Pharmaceuticals A/S
• Avadel Pharmaceuticals plc
• UroGen Pharma Ltd
• Sanwa Kagaku Co. Ltd.
• Urovant Sciences Inc
• Serenity Pharmaceuticals LLC
• Vantia Therapeutics Inc
• AA Pharma Inc
• Wellesley Pharmaceuticals Inc
What Are The Regional Insights Into The Nocturia Market?
North America was the largest region in the nocturia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nocturia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
